^
    Back
    Association details:
    Biomarker:PIK3CA N345K + PIK3CA N1044K
    Cancer:Breast Cancer
    Drug:Piqray (alpelisib) (PIK3CA inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    ASCO 2021
    Title:

    Real-world (rw) clinical outcomes on alpelisib (ALP) in patients (pts) with breast cancer (BC) and PIK3CA mutations (PIK3CAm). Add to Collection

    Published date:
    05/19/2021
    Excerpt:
    Cohort C: 36 pts with OTHERm only, any receptor subtype, treated with ALP in any combination....In Cohort C, rwPFS > 6 months was observed in 5 pts bearing: N345K, Q75E, R38C, G106_108del, and N345K/N1044K....there is evidence that OTHERm may differ in their degree of PI3K activation, oncogenicity, and ALP sensitivity.
    DOI:
    10.1200/JCO.2021.39.15_suppl.1068